To evaluate the suitability of CD133 as a target for CAR-T cell therapy in HCC, we first analysed CD133 protein levels in 67 HCC patient samples (stage I, 36 cases; stage II, 7 cases; stage III, 24 cases; stage IV, 26 lung metastasis cases) and matched adjacent tissue by IHC assay. This evidence concerns the gene PROM1 and hepatocellular carcinoma.